Orion Presents New Insights from Phase II CYPIDES Trial on ODM-208 at 2024 ASCO Symposium.

CBR-701 (SYS6002), a cutting-edge therapeutic agent aimed at Nectin-4, exhibits promising outcomes in initial human trials with Nectin-4 positive cancer patients.

Flare Therapeutics Unveils Design for FX-909's Early-Stage Trial with Dose Increasing and Widening Approach at ASCO's 2024 Urologic Cancer Conference.

LAVA Therapeutics reveals a partnership with Merck & Co., US, to assess the potential of combining LAVA-1207 with the treatment, KEYTRUDA®.

Sionna Therapeutics has revealed the administration of the initial dose to a healthy participant in the Stage 1 clinical study for SION-109.

Sciwind Biosciences Reports Encouraging Outcomes from Initial Clinical Study of XW004, Its Oral Version of Sustained-Release GLP-1 Mimetic Ecnoglutide.

Locus Biosciences has disclosed receiving a $23.9 million investment from BARDA, intended to back the inaugural Phase 2 study of its groundbreaking CRISPR-crafted phage treatment.

Onward Therapeutics has begun recruiting for an initial phase clinical study of their innovative dual-targeted antibody, OT-A201, which engages with two distinct immune control points.

PharmAbcine Initiates Dosing in Early-Stage Study for PMC-309 with KEYTRUDA (pembrolizumab) in Subjects Facing Severe Solid Cancers.

Harbour BioMed has been granted FDA approval to initiate human trials for their bispecific antibody, HBM9027, in the U.S.

Biosion has received approval from the FDA for its investigational new drug application concerning BSI-082, an innovative monoclonal antibody targeting SIRPα.

CDR-Life revealed the FDA's approval for clinical trial application for their drug, CDR404, aimed at addressing solid tumor conditions.